Skip to content
MarketScale
‹ Back to IndustriesSciences

POLYGON AT ARMA LIVE! IN ANAHEIM

ARMA Live! Is the premier event for information professionals to connect, learn, and shape the profession. This year’s event will be held in Anaheim, California, from October 22-24, and Polygon will be on hand in Booth #724 to meet you and showcase our important services. About ARMA ARMA is a non-profit organization whose mission is…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
POLYGON AT ARMA LIVE! IN ANAHEIM

Key takeaways

01

Is the premier event for information professionals to connect, learn, and shape the profession.

02

This year’s event will be held in Anaheim, California, from October 22-24, and Polygon will be on hand in Booth #724 to meet you and showcase our important services.

03

About ARMA ARMA is a non-profit organization whose mission is…

ARMA Live! Is the premier event for information professionals to connect, learn, and shape the profession. This year’s event will be held in Anaheim, California, from October 22-24, and Polygon will be on hand in Booth #724 to meet you and showcase our important services.

About ARMA

ARMA is a non-profit organization whose mission is to empower the community of information professionals to advance their careers, organizations, and the profession. In their ongoing efforts to be the driving force that enables organizations to harness the strategic power of information, each year they host ARMA Live!–a powerful event dedicated to the critical industry of information professionals.

About Live!

Those who manage and secure data are key players in almost every organization, and ARMA strives to support those who manage this critical asset for their teams. This year’s ARMA theme is the power of I. Information is power, especially when managed and leveraged by highly trained and knowledgeable information professionals. ARMA Live! is a great opportunity to meet with other superheroes in the exploding field of information management.

Polygon’s Services

Polygon is thrilled to be participating in this year’s event. Our organization has dedicated document restoration facilities throughout the United States and offers the most advanced techniques for document recovery and complete media restoration. Our vacuum freeze-drying process is the most efficient and effective method for the drying of wet papers and other documents.

In addition, we utilize state-of-art recovery and protection services in desiccant air drying, cleaning and sterilization, and digital imaging. Our complete offerings include paper, books, blueprints, X-rays, film restoration, copying, and scanning services. We invite you to stop by Booth #724 in Anaheim to discover more about these processes.

To learn more about the critical role of Polygon in supporting the information industry, visit us online today!

Read more at polygongroup.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512